Literature DB >> 16950855

Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Paul Balmer1, Andrew J Cant, Ray Borrow.   

Abstract

Measuring and interpretation of the immune response to pneumococcal polysaccharides is a complex field, owing to the diversity of the pneumococcal polysaccharide capsular types, different vaccine formulations including both polysaccharide and conjugate vaccines, diverse pneumococcal serological assays, lack of immunogenicity data for the conjugate in a number of at-risk groups and complex vaccine schedules. Even the reasons for performing pneumococcal serology can be complex, as assays may be performed for one of two reasons: either to assess an individual's immune status to the pneumococcus or to discriminate between normal and abnormal humoral immunity. This review details a history of the pneumococcal serological assays and provides some insight into when serology can prove useful, including vaccination data for certain at-risk groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950855      PMCID: PMC2001126          DOI: 10.1136/jcp.2006.041210

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  58 in total

1.  Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants.

Authors:  M Väkeväinen; C Eklund; J Eskola; H Käyhty
Journal:  J Infect Dis       Date:  2001-08-14       Impact factor: 5.226

Review 2.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

3.  Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT.

Authors:  P Ljungman; D Engelhard; R de la Cámara; H Einsele; A Locasciulli; R Martino; P Ribaud; K Ward; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2005-04       Impact factor: 5.483

4.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

5.  A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers.

Authors:  M D Blum; R Dagan; P M Mendelman; V Pinsk; M Giordani; S Li; N Bohidar; T B McNeely
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

6.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-10-06

7.  Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.

Authors:  P Richmond; E Kaczmarski; R Borrow; J Findlow; S Clark; R McCann; J Hill; M Barker; E Miller
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

8.  Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

Authors:  J MacLennan; S Obaro; J Deeks; D Lake; C Elie; G Carlone; E R Moxon; B Greenwood
Journal:  J Infect Dis       Date:  2000-11-15       Impact factor: 5.226

9.  A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides.

Authors:  Jerry W Pickering; Thomas B Martins; Ryan W Greer; M Carl Schroder; Mark E Astill; Christine M Litwin; Stephen W Hildreth; Harry R Hill
Journal:  Am J Clin Pathol       Date:  2002-04       Impact factor: 2.493

10.  Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation.

Authors:  Deborah C Molrine; Joseph H Antin; Eva C Guinan; Robert J Soiffer; Kristin MacDonald; Richard Malley; Frank Malinoski; Susan Trocciola; Marjorie Wilson; Donna M Ambrosino
Journal:  Blood       Date:  2002-09-19       Impact factor: 22.113

View more
  9 in total

Review 1.  Measuring immune responses to pneumococcal vaccines.

Authors:  David C LaFon; Moon H Nahm
Journal:  J Immunol Methods       Date:  2018-08-08       Impact factor: 2.303

2.  Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency.

Authors:  F M Cavaliere; C Milito; H Martini; M Schlesier; R Dräger; K Schütz; G Brunetti; A M Pesce; V Thon; K Warnatz; I Quinti
Journal:  J Clin Immunol       Date:  2012-12-29       Impact factor: 8.317

Review 3.  Practical review of immunizations in adult patients with cancer.

Authors:  Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Hum Vaccin Immunother       Date:  2015-06-25       Impact factor: 3.452

4.  Impact of analytical variability on clinical interpretation of multiplex pneumococcal serology assays.

Authors:  Xiaochun Zhang; Kelly Simmerman; Belinda Yen-Lieberman; Thomas M Daly
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

5.  Optimal assessment of the ability of children with recurrent respiratory tract infections to produce anti-polysaccharide antibodies.

Authors:  D Tuerlinckx; F Vermeulen; V Pékus; G de Bilderling; Y Glupczynski; S Collet; J Jamart; E Bodart; F Mascart
Journal:  Clin Exp Immunol       Date:  2007-05-18       Impact factor: 4.330

6.  Memory B cells and pneumococcal antibody after splenectomy.

Authors:  Heather Wasserstrom; James Bussel; Lony C-L Lim; Charlotte Cunningham-Rundles
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

7.  A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine.

Authors:  C R Laratta; K Williams; D Vethanayagam; M Ulanova; H Vliagoftis
Journal:  Allergy Asthma Clin Immunol       Date:  2017-06-07       Impact factor: 3.406

8.  Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial.

Authors:  Lykke Larsen; Claus Bistrup; Søren Schwartz Sørensen; Lene Boesby; Charlotte Sværke Jørgensen; Christian Nielsen; Isik Somuncu Johansen
Journal:  Vaccines (Basel)       Date:  2022-07-07

9.  Focusing on Good Responders to Pneumococcal Polysaccharide Vaccination in General Hospital Patients Suspected for Immunodeficiency. A Decision Tree Based on the 23-Valent Pneumococcal IgG Assay.

Authors:  Lisanne M A Janssen; Michiel Heron; Jean-Luc Murk; Alexander C A P Leenders; Ger T Rijkers; Esther de Vries
Journal:  Front Immunol       Date:  2019-11-05       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.